Ripasudil hydrochloride hydrate (K-115), a novel rho kinase inhibitor, provides statistically significant intraocular pressure (IOP)–lowering effects and has a tolerable safety profile. However, no studies have evaluated ripasudil combined with β-blockers and prostaglandin analogues.
To evaluate the additive IOP-lowering effects and the safety of ...
JAMA Ophthalmol. Published online April 16, 2015. doi:10.1001/jamaophthalmol.2015.0525